Patterns of CMV Infection after Letermovir Withdrawal in Recipients of Post-Transplant Cyclophosphamide Based Transplant

Reactivation of latent cytomegalovirus (CMV) is increased in CMV seropositive (CMV+) recipients of allogeneic hematopoietic cell transplantation (allo HCT) using post-transplant cyclophosphamide (PT-Cy) based graft versus host disease prophylaxis. Letermovir, a novel DNA terminase complex inhibitor, reduces the incidence of clinically significant CMV infection (csCMVi) in this population. We and others have demonstrated that extended use of letermovir is effective in recipients of PT-Cy; however, late csCMVi is a frequent complication that can occur after letermovir withdrawal.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrew Lin, Samantha Brown, Ms. Stephanie Chinapen, Yeon Joo Lee, Susan K. Seo, Doris M. Ponce, Zainab Shahid, Sergio A. Giralt, Genovefa A Papanicolaou, Miguel-Angel Perales, Brian C. Shaffer Tags: 115 Source Type: research